Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: An interim report

Diabetes, Obesity and Metabolism

Volumn 11, Issue 2, 2009, Pages 150-156

  Abraira, Carlos ^a   Duckworth, W C ^b   Moritz, T ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Glycaemic control; Lipids

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; GLYCEMIC CONTROL; HUMAN; INTERMETHOD COMPARISON; LIFESTYLE; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VITRECTOMY;

EID: 58149345990     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00933.x     Document Type: Article

References (28)

1. Geiss S, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH eds. Diabetes in America, 2nd edn. Bethesda, MD: National Institutes of Health, 1995; 133-155 (NIH publ. no. 95-1468).
2. Selvin E, Marinopoulos S, Berkenbilt G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
3. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
4. Smith NL, Chen L, Au DH, McDonnell M, Fihn SD. Cardiovascular risk factor control among veterans with diabetes. Diabetes Care 2004; 27 (Suppl. 2): B33-B38.
5. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268.
6. Abraira C, Colwell J, Nuttall F et al. Cardiovascular events and correlates in the VA Feasibility Trial (VA CSDM). Arch Intern Med 1997; 157: 181-188.
7. Levin S, Coburn JW, Abraira C et al: The effect of intensive glycemic control on micro-albuminuria in type 2 diabetes mellitus. Diabetes Care 2000; 23: 1478-1485.
8. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. Vijan S, Hofer T, Hayward R. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997; 127: 788-795.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
11. Abraira C, Duckworth W, McCarren M et al. Design of the Cooperative Study on glycemic control and complications in Diabetes Mellitus type 2: the VADT. J Diabetes Complications 2003; 17: 314-322.
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007; 30 (Suppl. 1): S4-S41
13. Emanuele N, Sacks J, Klein R et al. Ethnicity, race, and baseline retinopathy correlates in the Veterans Affairs Diabetes Trial. Diabetes Care 2005; 28: 1954-1958.
14. Duckworth W, McCarren M, Abraira C. The Department of Veterans Affairs Diabetes Trial. Diabetes Care 2001; 24: 942-945.
15. Abraira C, Duckworth W. The need for glycemic trials in type 2 diabetes. Clinical Diabetes 2003; 21: 107-111.
16. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C. The association between metabolic control and prevalent cardiovascular disease in type 2 Diabetes. The VA Cooperative Study in Diabetes. J Diabetes Complications 2006; 20: 75-80.
17. Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993; 269: 1290-1291.
18. Weinstock RS, Hawley G, Repke D, Feurstein BL, Sawin CT, Pogach LM. Pharmacy costs and glycemic control in the Department of Veterans Affairs. Diabetes Care 2004; 27 (Suppl. 2): B74-B81.
19. Pogach LM, Brietzke SA, Cowan CL, Conlin P, Walder DJ, Sawin CT. Development of evidence-based clinical practice guidelines for diabetes: the Department of Veterans Affairs/Department of Defense guidelines initiative. Diabetes Care 2004; 27 (Suppl. 2): B82-B89.
20. American College of Physicians. Glycemic control and type 2 diabetes mellitus. Ann Intern Med 2007; 147: 417-422.
21. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
22. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians. Ann Intern Med 2004; 140: 650-658.
23. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-609.
24. Ferris FL, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Diabetes Care 1996; 19: 1291-1292.
25. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB 2004; 18: 805-815.
26. Meyers CD, McCarren M, Wong ND et al. Baseline achievement of lipid goals and usage of lipid medications in the VA diabetes trial. Am J Cardiology 2006; 98: 63-65.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med 2007; 356: 2457-2471.
28. ACCORD Trial Press Release. Available from URL: http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551. February 6, Accessed 21 April 2008.